296 related articles for article (PubMed ID: 20133964)
1. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C; Harnett M; Dobs AS; Swerdloff RS
J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
3. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
4. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men.
Qoubaitary A; Meriggiola C; Ng CM; Lumbreras L; Cerpolini S; Pelusi G; Christensen PD; Hull L; Swerdloff RS; Wang C
J Androl; 2006; 27(6):853-67. PubMed ID: 16837736
[TBL] [Abstract][Full Text] [Related]
6. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
[TBL] [Abstract][Full Text] [Related]
7. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
Moisey R; Swinburne J; Orme S
Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
[TBL] [Abstract][Full Text] [Related]
8. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
Saad F; Kamischke A; Yassin A; Zitzmann M; Schubert M; Jockenhel F; Behre HM; Gooren L; Nieschlag E
Asian J Androl; 2007 May; 9(3):291-7. PubMed ID: 17486268
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
[TBL] [Abstract][Full Text] [Related]
10. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
Yassin AA; Saad F
Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
[TBL] [Abstract][Full Text] [Related]
12. Which testosterone replacement therapy?
Cantrill JA; Dewis P; Large DM; Newman M; Anderson DC
Clin Endocrinol (Oxf); 1984 Aug; 21(2):97-107. PubMed ID: 6467640
[TBL] [Abstract][Full Text] [Related]
13. Testosterone undecanoate in the treatment of male hypogonadism.
Edelstein D; Basaria S
Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
[TBL] [Abstract][Full Text] [Related]
16. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men.
Raynaud JP; Legros JJ; Rollet J; Augès M; Bunouf P; Sournac M; Fiet J
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):168-76. PubMed ID: 18325757
[TBL] [Abstract][Full Text] [Related]
18. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
19. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men.
Amory JK; Anawalt BD; Blaskovich PD; Gilchriest J; Nuwayser ES; Matsumoto AM
J Androl; 2002; 23(1):84-91. PubMed ID: 11780927
[TBL] [Abstract][Full Text] [Related]
20. Body fat content and testosterone pharmacokinetics determine gonadotropin suppression after intramuscular injections of testosterone preparations in normal men.
Kornmann B; Nieschlag E; Zitzmann M; Gromoll J; Simoni M; von Eckardstein S
J Androl; 2009; 30(5):602-13. PubMed ID: 19342702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
